By activating GIP receptors, tirzepatide may enhance insulin secretion in a glucose-dependent manner, meaning it stimulates insulin release primarily when blood glucose levels are elevated, potentially reducing the risk of hypoglycemia
Lilly is aiming to eliminate misperceptions about this disease and transform how it can be managed. Leonard Glass, MD, senior vice president global medical affairs, Lilly Diabetes and Obesity Zepbound is expected to be available in the U.S
At week 40, mean dose of insulin glargine was 38, 36, 29, and 59 units/day for patients receiving MOUNJARO 5 mg, 10 mg, 15 mg, and placebo, respectively
Track where pricing, margin distribution or market positioning are out of line with competitors, exchanges or expected performance patterns before sharp money finds the gap
Do not eat right after your injection